E-LIB Suche - Ergebnisse für: McDermott, David

1

14 Natural killer cells have impaired cytotoxicity in advan..:

Moritz, Vivien ; Xu, Wenxin ; Birch, Grace...
The Oncologist. 29 (2024) Supplement_1 - p. S7-S8 , 2024

Link: https://doi.org/10.1093/..

2

17 CDK4/6 inhibition with Abemaciclib in in patients (pts) ..:

McGregor Dr, Bradley ; Xie, Wanling ; Xu, Wenxin...
The Oncologist. 29 (2024) Supplement_1 - p. S1-S1 , 2024

Link: https://doi.org/10.1093/..

3

Safety profile of pembrolizumab monotherapy based on an agg..:

Brahmer, Julie R. ; Long, Georgina V. ; Hamid, Omid...
European Journal of Cancer. 199 (2024) - p. 113530 , 2024

Link: https://doi.org/10.1016/..

4

Combinatorial biomarker for predicting outcomes to anti-PD-..:

Deutsch, Julie Stein ; Lipson, Evan J. ; Danilova, Ludmila...
Cell Reports Medicine. 4 (2023) 2 - p. 100947 , 2023

Link: https://doi.org/10.1016/..

5

Circulating and intratumoral immune determinants of respons..:

Saliby, Renee Maria ; El Zarif, Talal ; Bakouny, Ziad...
The Oncologist. 28 (2023) Supplement_1 - p. S15-S16 , 2023

Link: https://doi.org/10.1093/..

6

Adjuvant ipilimumab and nivolumab in renal cell carcinoma: ..:

Vogl, Ursula Maria ; McDermott, David ; Powles, Thomas
The Lancet. 401 (2023) 10379 - p. 796-798 , 2023

Link: https://doi.org/10.1016/..

7

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atez..:

Gomez-Roca, Carlos ; Cassier, Philippe ; Zamarin, Dmitriy...
Journal for ImmunoTherapy of Cancer. 10 (2022) 5 - p. e004076 , 2022

Link: https://doi.org/10.1136/..

8

Avelumab Plus Axitinib as First-Line Therapy for Advanced R..:

Larkin, James ; Oya, Mototsugu ; Martignoni, Marcella...
The Oncologist. 28 (2022) 4 - p. 333-340 , 2022

Link: https://doi.org/10.1093/..

9

First-line Nivolumab plus Ipilimumab Versus Sunitinib in Pa..:

Albiges, Laurence ; Tannir, Nizar M. ; Burotto, Mauricio...
European Urology. 81 (2022) 3 - p. 266-271 , 2022

Link: https://doi.org/10.1016/..

10

Wessex and the Reign of Edmund II Ironside:

, In: The land of the English kin / edited by Alexander Langlands, Ryan Lavelle

McDermott, David. (2020) - p. 336-354

Exemplar: Zentrale:Magazin 03.d.3250

11

Impact of COVID-19 pandemic on treatment patterns in metast..:

Aeppli, Stefanie ; Eboulet, EricInnocents ; Eisen, Tim...
ESMO Open. 5 (2020) - p. e000852 , 2020

Link: https://doi.org/10.1136/..

12

Nivolumab plus ipilimumab versus sunitinib for first-line t..:

Albiges, Laurence ; Tannir, Nizar M. ; Burotto, Mauricio...
ESMO Open. 5 (2020) 6 - p. e001079 , 2020

Link: https://doi.org/10.1136/..

13

High-Dose Ipilimumab and High-Dose Interleukin-2 for Patien..:

Silk, Ann W. ; Kaufman, Howard L. ; Curti, Brendan...
Frontiers in Oncology. 9 (2020) - p. , 2020

Link: https://doi.org/10.3389/..

14

Wessex and the Reign of Edmund ii Ironside:

, In: The Land of the English Kin,

McDermott, David - p. 336-351 , 2020

Link: https://doi.org/10.1163/..

15

To treat or not to treat: Patient exclusion in immune oncol..:

Pantuck, Morgan ; McDermott, David ; Drakaki, Alexandra
Cancer. 125 (2019) 20 - p. 3506-3513 , 2019

Link: https://doi.org/10.1002/..